journal article·2018-11-05Open access

Induction of Th1 type-oriented humoral response through intranasal immunization of mice with SAG1-Toxoplasma gondiipolymeric nanospheres

Huma Naeem, Madiha Sana, Saher Islam, Matiullah Khan, Farooq Riaz, Zunaira Zafar, Haroon Akbar, Wasim Shehzad, Imran Rashid

Abstract

About one-third of the world population is prone to have infection with T. gondii, which can cause toxoplasmosis in the developing fetus and in people whose immune system is compromised through disease or chemotherapy. Surface antigen-1 (SAG1) is the candidate of vaccine against toxoplasmosis. Recent advances in biotechnology and nano-pharmaceuticals have made possible to formulate nanospheres of recombinant protein, which are suitable for sub-unit vaccine delivery. In current study, the local strain was obtained from cat feces as toxoplasma oocysts. Amplified 957 bp of SAG1 was cloned into pGEM-T and further sub-cloned into pET28-SAG1. BL21 bacteria were induced at different concentrations of isopropyl β-d-1-thiogalactopyranoside for the expression of rSAG1 protein. An immunoblot was developed for the confirmation of recombinant protein expression at 35 kDa that was actually recognized by anti-HIS antibodies and sera were collected from infected mice. PLGA encapsulated nanospheres of recombinant SAG1 were characterized through scanning electron microscopy. Experimental mice were intraperitoneally immunized with rSAG1 protein and intra-nasally immunized with nanosphere. The immune response was evaluated by indirect ELISA. In results intra-nasally administered rSAG1 in nanospheres appeared to elicit elevated responses of specific IgA and IgG2a than in control. Nanospheres of rSAG1 are found to be a bio-compatible candidate for the development of vaccine against T. gondii.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Toxoplasma gondii Research Studies · Herpesvirus Infections and Treatments · Rabies epidemiology and control

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Parasitology, University of Veterinary and Animal Sciences, Lahore, Pakistan;

Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Pakistan

Funding

Grand Challenges Canada

References (71)

Show source-provided references
1. 10.1046/j.1469-0691.2002.00485.x10.1046/j.1469-0691.2002.00485.x ↗
2. 10.1016/S0020-7519(00)00124-710.1016/S0020-7519(00)00124-7 ↗
3. 10.1016/B978-012369542-0/50008-810.1016/B978-012369542-0/50008-8 ↗
4. 10.1371/journal.pone.009020310.1371/journal.pone.0090203 ↗
5. 10.1186/1756-3305-4-16510.1186/1756-3305-4-165 ↗
6. McLeod R · Curr Clin Top Infect Dis · 2000 · 20 · 189
7. 10.1186/1756-3305-6-1510.1186/1756-3305-6-15 ↗
8. 10.1016/j.meegid.2012.01.01310.1016/j.meegid.2012.01.013 ↗
9. 10.1093/clinids/15.2.21110.1093/clinids/15.2.211 ↗
10. 10.1128/CMR.11.2.26710.1128/CMR.11.2.267 ↗
11. 10.1111/j.1863-2378.2009.01279.x10.1111/j.1863-2378.2009.01279.x ↗
12. 10.1016/j.ijpara.2009.06.00910.1016/j.ijpara.2009.06.009 ↗
13. 10.1017/S003118200000144X10.1017/S003118200000144X ↗
14. 10.4269/ajtmh.1991.44.38210.4269/ajtmh.1991.44.382 ↗
15. 10.1016/S1286-4579(03)00048-010.1016/S1286-4579(03)00048-0 ↗
16. 10.1590/S0074-0276200900020001910.1590/S0074-02762009000200019 ↗
17. 10.1017/S003118200006669510.1017/S0031182000066695 ↗
18. 10.1016/j.exppara.2006.02.00510.1016/j.exppara.2006.02.005 ↗
19. 10.1016/S0264-410X(98)00039-510.1016/S0264-410X(98)00039-5 ↗
20. 10.1128/IAI.66.9.4503-4506.199810.1128/IAI.66.9.4503-4506.1998 ↗
21. 10.1128/IAI.71.11.6615-6619.200310.1128/IAI.71.11.6615-6619.2003 ↗
22. 10.1007/s00436-003-0992-510.1007/s00436-003-0992-5 ↗
23. 10.1016/j.ijpharm.2006.05.06810.1016/j.ijpharm.2006.05.068 ↗
24. 10.1517/17425247.2013.76995610.1517/17425247.2013.769956 ↗
25. Jain S · The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant · 2011 · 10 · 1731
26. 10.1002/jbm.1001910.1002/jbm.10019 ↗
27. 10.1088/0957-4484/23/32/32510110.1088/0957-4484/23/32/325101 ↗
28. 10.1016/S0020-7519(03)00053-510.1016/S0020-7519(03)00053-5 ↗
29. 10.1016/S0168-3659(03)00194-910.1016/S0168-3659(03)00194-9 ↗
30. Akagi T · 2012 · 31
31. 10.1016/S0169-409X(98)00012-X10.1016/S0169-409X(98)00012-X ↗
32. 10.3390/polym303137710.3390/polym3031377 ↗
33. 10.1093/intimm/dxu06310.1093/intimm/dxu063 ↗
34. Birkhoff M · Ind J Pharm Sci · 2009 · 71 · 729
35. 10.1016/j.vaccine.2010.06.12110.1016/j.vaccine.2010.06.121 ↗
36. 10.1016/S0264-410X(02)00191-310.1016/S0264-410X(02)00191-3 ↗
37. 10.1128/IAI.64.6.2158-2166.199610.1128/IAI.64.6.2158-2166.1996 ↗
38. Elson CO · J Immunol · 1984 · 132 · 273610.4049/jimmunol.132.6.2736 ↗
39. 10.1080/1061186070163796610.1080/10611860701637966 ↗
40. Nabi H · J Pak Med Assoc · 2018 · 68 · 115
41. 10.1007/s00436-016-5298-510.1007/s00436-016-5298-5 ↗
42. 10.1093/bioinformatics/bts19910.1093/bioinformatics/bts199 ↗
43. Sambrook J · 1989
44. 10.1093/nar/gkg52610.1093/nar/gkg526 ↗
45. 10.1093/nar/gkn19810.1093/nar/gkn198 ↗
46. 10.1093/nar/gkm23410.1093/nar/gkm234 ↗
47. Gostel MR · Development of novel, Exon-Primed Intron-Crossing (EPIC) markers from EST databases and evaluation of their phylogenetic utility in Commiphora (Burseraceae) · 2014 · 2 · 1300098
48. 10.1016/j.pep.2005.10.00210.1016/j.pep.2005.10.002 ↗
49. 10.1104/pp.109.13712510.1104/pp.109.137125 ↗
50. 10.1038/227680a010.1038/227680a0 ↗
51. 10.1016/j.vaccine.2011.09.09910.1016/j.vaccine.2011.09.099 ↗
52. McCall RL · J Visual Exp · 2013 · 51015
53. 10.1586/14760584.2013.84465210.1586/14760584.2013.844652 ↗
54. 10.1016/0166-6851(88)90075-810.1016/0166-6851(88)90075-8 ↗
55. Murray A · Multiple B cell epitopes in a recombinant GRA2 secreted antigen of Toxoplasma gondii · 1993 · 34 · 235
56. 10.4049/jimmunol.164.7.374110.4049/jimmunol.164.7.3741 ↗
57. 10.1586/erv.09.2710.1586/erv.09.27 ↗
58. Allahyari M · Res Pharm Science · 2012 · 7 · 268
59. 10.1586/14760584.4.2.18510.1586/14760584.4.2.185 ↗
60. 10.1016/S0264-410X(02)00435-810.1016/S0264-410X(02)00435-8 ↗
61. 10.1007/s00795-006-0335-610.1007/s00795-006-0335-6 ↗
62. 10.1016/j.ijpharm.2004.09.00210.1016/j.ijpharm.2004.09.002 ↗
63. 10.1016/j.ejpb.2006.07.01610.1016/j.ejpb.2006.07.016 ↗
64. 10.1023/A:101106323225710.1023/A:1011063232257 ↗
65. 10.1016/j.jconrel.2004.11.01210.1016/j.jconrel.2004.11.012 ↗
66. 10.1186/1756-3305-6-3410.1186/1756-3305-6-34 ↗
67. 10.1016/j.exppara.2013.04.00210.1016/j.exppara.2013.04.002 ↗
68. 10.1007/s00436-015-4652-310.1007/s00436-015-4652-3 ↗
69. 10.1002/path.187710.1002/path.1877 ↗
70. 10.1016/j.vaccine.2004.04.02210.1016/j.vaccine.2004.04.022 ↗
71. 10.1016/j.vaccine.2010.01.03110.1016/j.vaccine.2010.01.031 ↗